CD274 and neoplasm: In this review, we discuss the advances that have been made in generating immunotherapeutic alternatives to CTLA-4 and PD-1/PD-L1 in experimental model systems of solid tumours, as well as highlighting the challenges in treating secondary tumours with immunotherapy.